Safety Profile
Known Safety Concerns
- Antiplatelet and anticoagulant effect -- caution with warfarin and aspirin
- CYP3A4 inhibition -- drug interaction potential
- Rare allergic reactions
- Generally well tolerated at standard doses
Contraindications
- Antiplatelet and anticoagulant effect -- caution with warfarin and aspirin
- CYP3A4 inhibition -- drug interaction potential
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Rutin is a quercetin glycoside used for capillary fragility, venous insufficiency, and as an antioxidant. It inhibits platelet aggregation and has anticoagulant properties. CYP3A4 inhibitor — drug interaction potential. Well tolerated at standard doses.
Biological and Chemical Classification
- Scientific Name
- Rutin (quercetin-3-rutinoside) from Sophora japonica
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- Antiplatelet and anticoagulant effect -- caution with warfarin and aspirin
- CYP3A4 inhibition -- drug interaction potential
- Rare allergic reactions
- Generally well tolerated at standard doses
The available scientific evidence for Rutin indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 25 მარ 2026, 17:36
Evidence Distribution
-
Observational / other LOW evidence YELLOWModification of Gliadin with Rha/PGA/Ta for Rutin-Loaded Hollow Nanoparticles: Preparation, Properties, and In Vitro Digestion. ↗Gao J et al.. Modification of Gliadin with Rha/PGA/Ta for Rutin-Loaded Hollow Nanoparticles: Preparation, Properties, and In Vitro Digestion.. J Agric Food Chem. 2026. PMID:41877386.PMID 41877386 ↗Journal J Agric Food ChemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41877386/
-
Observational / other LOW evidence YELLOWTi(3)C(2)/CuCoSe(2) p-n Heterojunction: Preparation and Mechanism for Machine Learning-enhanced Electrochemical Sensing of Rutin. ↗Li Q et al.. Ti(3)C(2)/CuCoSe(2) p-n Heterojunction: Preparation and Mechanism for Machine Learning-enhanced Electrochemical Sensing of Rutin.. Anal Chem. 2026. PMID:41877376.PMID 41877376 ↗Journal Anal ChemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41877376/
-
Observational / other LOW evidence YELLOWInsights into the flavonoid composition and antioxidant activity of Jeramon, a novel Korean lemon cultivar. ↗Lee CD et al.. Insights into the flavonoid composition and antioxidant activity of Jeramon, a novel Korean lemon cultivar.. Food Chem. 2026. PMID:41875772.PMID 41875772 ↗Journal Food ChemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41875772/
-
Observational / other LOW evidence YELLOWBeneficial rhizobacteria and virus infection modulate the soybean metabolome and influence the feeding preferences of the virus vector Epilachna varivestis. ↗Pulido H et al.. Beneficial rhizobacteria and virus infection modulate the soybean metabolome and influence the feeding preferences of the virus vector Epilachna varivestis.. New Phytol. 2026. PMID:41874262.PMID 41874262 ↗Journal New PhytolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41874262/
-
Observational / other LOW evidence YELLOWTargeting Quorum Sensing LsrR Protein in E. coli: A Computational Approach to Screen the Plant Bioactive Compounds as Inhibitors of Biofilm Formation… ↗Vijaya Prabhu S et al.. Targeting Quorum Sensing LsrR Protein in E. coli: A Computational Approach to Screen the Plant Bioactive Compounds as Inhibitors of Biofilm Formation in Urinary Tract Infections.. Assay Drug Dev Technol. 2026. PMID:41869957.PMID 41869957 ↗Journal Assay Drug Dev TechnolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41869957/
-
Observational / other LOW evidence YELLOWOptimized extraction of polyphenols from rooibos tea (Aspalathus linearis) and their biological activities. ↗Othman MM et al.. Optimized extraction of polyphenols from rooibos tea (Aspalathus linearis) and their biological activities.. Front Nutr. 2026. PMID:41867690.PMID 41867690 ↗Journal Front NutrYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41867690/
-
Observational / other LOW evidence YELLOWPhenolic-Enriched Pullulan Coatings: Molecular Interactions and Functional Properties for Active Food Packaging Applications. ↗John A et al.. Phenolic-Enriched Pullulan Coatings: Molecular Interactions and Functional Properties for Active Food Packaging Applications.. ACS Omega. 2026. PMID:41867551.PMID 41867551 ↗Journal ACS OmegaYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41867551/
-
Observational / other LOW evidence YELLOWMultifunctional silver nanoparticles-loaded rutin functionalised sodium alginate beads: Catalysis, corrosion resistance, bactericidal and anti-oxidant studies. ↗Samal S et al.. Multifunctional silver nanoparticles-loaded rutin functionalised sodium alginate beads: Catalysis, corrosion resistance, bactericidal and anti-oxidant studies.. Int J Biol Macromol. 2026. PMID:41865933.PMID 41865933 ↗Journal Int J Biol MacromolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41865933/
-
Observational / other LOW evidence YELLOWDivergent Biochemical Strategies and Organ-Specific Metabolic Adjustments in Spinach Mediated by Exogenous Amino Acids Under Salt Stress. ↗Turfan N et al.. Divergent Biochemical Strategies and Organ-Specific Metabolic Adjustments in Spinach Mediated by Exogenous Amino Acids Under Salt Stress.. Physiol Plant. 2026. PMID:41858176.PMID 41858176 ↗Journal Physiol PlantYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41858176/
-
Observational / other LOW evidence YELLOWA Biomimetic Protein Immobilization Method for Studying Drug-Protein Interactions Based on Affinity Capillary Electrochromatography. ↗Cui J et al.. A Biomimetic Protein Immobilization Method for Studying Drug-Protein Interactions Based on Affinity Capillary Electrochromatography.. Electrophoresis. 2026. PMID:41858158.PMID 41858158 ↗Journal ElectrophoresisYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41858158/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Rutin. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Rutin
A score of 3.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.